Research programme: janus kinase inhibitors - Aclaris Therapeutics

Drug Profile

Research programme: janus kinase inhibitors - Aclaris Therapeutics

Alternative Names: Baricitinib - Aclaris Therapeutics; Decernotinib - Aclaris Therapeutics; JAK inhibitors; Ruxolitinib - Aclaris Therapeutics

Latest Information Update: 23 May 2017

Price : $50

At a glance

  • Originator Columbia University
  • Developer Aclaris Therapeutics
  • Class Pyrazoles; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Janus kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Vitiligo
  • Research Alopecia

Most Recent Events

  • 05 Apr 2017 Aclaris Therapeutics receives patent allowance for methods related to the use and administration of baricitinib and decernotinib for treating hair loss disorders and for inducing hair growth in USA
  • 31 Oct 2016 Columbia University has patent protection for Janus kinase inhibitors in USA and Japan
  • 11 Aug 2016 Preclinical trials in Vitiligo in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top